Status: Recruiting
A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients
This Trial is an open-label, multicenter trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ETH-155008 in subjects with AML and NHL who previously received standard treatment or are ineligible for standard treatment options.
Participants needed: 60
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Shengke Pharmaceuticals (Jiangsu) Limited, ChinaUpdated: May 8, 2024Locations: 2
Eligibility criteria
Be at least 18 years of age and < 80 years old. [+26]
Acute promyelocytic leukemia, acute mixed phenotypic leukemia, acute myeloid leu... [+44]